RT Journal Article
SR Electronic
T1 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A811
OP A811
DO 10.1136/jitc-2023-SITC2023.0716
VO 11
IS Suppl 1
A1 Dumbrava, Ecaterina
A1 Mestres, Joan Albanell
A1 Ascierto, Paolo Antonio
A1 Blay, Jean-Yves
A1 Champiat, Stéphane
A1 Salgado, Alfonso Cortes
A1 Deleuze, Antoine
A1 GilMartin, Marta
A1 Heeke, Arielle
A1 Italiano, Antoine
A1 Kang, Yoon-Koo
A1 Lee, Jeeyun
A1 Lee, Keun-Wook
A1 Losurdo, Agnese
A1 Magni, Michele
A1 Moore, Kathleen
A1 Benzaquen, Ana Oaknin
A1 Zabalza, Ignacio Ortego
A1 Park, Haeseong
A1 Rodriguez, Luis Paz-Ares
A1 Pegram, Mark D
A1 Ponz-Sarvise, Mariano
A1 Rasco, Drew
A1 Sharma, Manish
A1 Shergill, Ardaman
A1 Spano, Jean-Philippe
A1 Spira, Alexander I
A1 Vicier, Cecile
A1 Victoria, Ivan
A1 Weinberg, Benjamin
A1 Tapia, Coya
A1 Ptacek, Jason
A1 Alonso, Michael N
A1 Xu, Lu
A1 Yin, Ming
A1 Perez, Edith A
A1 Li, Bob T
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A811.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.